Pharmacogenomics Journal

Aims & Scope

The Pharmacogenomics Journal is a print and electronic journal, which is dedicated to the rapid publication of original research on pharmacogenomics and its clinical applications. Key areas of coverage include: Effects of genetic variability on drug toxicity and efficacy Identification and functional characterization of polymorphisms relevant to drug action Integration of new developments in the genome project and proteomics into clinical medicine, pharmacology, and therapeutics Clinical implementation of pharmacogenomics Identification of novel genomic targets for drug development Economics of genome-guided interventions ELSI issues on the clinical implementation of pharmacogenomics Pharmacogenomics in developing countries Companion diagnostics and drug development Supporting the Sustainable Developmental Goals We are proud to acknowledge that over 50% of the articles published in The Pharmacogenomics Journal in 2025 were related to one or more of the 17 Sustainable Development Goals (SDGs). Springer Nature supports the SDGs through a dedicated SDG Programme and is a signatory of the SDG Publishers Compact.

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Subject Classification